The potential for antitumor vaccination in acute myelogenous leukemia

While many advances have been made in the treatment of patients with cancer, significant challenges that remain include tumor cell resistance and the toxicity associated with currently used intensive chemotherapeutic regimens. This is particularly true for patients with acute myelogenous leukemia (A...

Full description

Saved in:
Bibliographic Details
Published in:Journal of molecular medicine (Berlin, Germany) Germany), 1998-02, Vol.76 (2), p.80-93
Main Author: ARCECI, R. J
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
Animals
Antigens, Neoplasm - immunology
Antineoplastic agents
Biological and medical sciences
Cancer vaccines
Cancer Vaccines - immunology
Disease Models, Animal
Drug resistance
Forecasting
Hematopoietic stem cells
Humans
Immunotherapy
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - immunology
Leukemia, Myeloid, Acute - prevention & control
Leukemia, Myeloid, Acute - therapy
Medical sciences
Patients
Pharmacology. Drug treatments
Remission
Stem cell transplantation
Toxicity
Tumors
Vaccination
Vaccines
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:While many advances have been made in the treatment of patients with cancer, significant challenges that remain include tumor cell resistance and the toxicity associated with currently used intensive chemotherapeutic regimens. This is particularly true for patients with acute myelogenous leukemia (AML). Most patients with AML usually are able to achieve complete remission, but only a minority obtain long-term survival. In addition, much of the success achieved has been due to escalation of chemotherapeutic dosing and hematopoietic stem cell transplantation. There is thus a great need for improved therapies which would ideally be able to circumvent drug resistance and more specifically target leukemic cells. Advances in immunobiology over the past century have led to new hope for the development of immune-mediated vaccine therapies for patients with cancer. This review focuses on the development of vaccine approaches for treatment of AML and some of the potential advantages and problems.
ISSN:0946-2716
1432-1440
DOI:10.1007/s001090050195